Quinn Reilly
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Quinn Reilly has a total of 22 co-authors. Here are the top co-authors by number of shared publications:
- Alan L. Ho
Head and Neck Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA
6 shared publications - Alison Elizabeth Smith
Kura Oncology, Inc., San Diego, California
6 shared publications - Amaya Gasco Hernandez
Foundation Medicine Inc, Boston, MA
6 shared publications - Andrew Saunders
Kura Oncology, Inc., Boston, Massachusetts
6 shared publications - Asako McCloskey
Molecular and Cell Biology Laboratory, The Salk Institute for Biological Studies, La Jolla, CA 92037, USA
6 shared publications - Ashley Dayoub
Kura Oncology, Inc., Boston, Massachusetts
6 shared publications
Latest Publications
- Open Access
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary figures S1-S5 from Tipifarnib Potentiates the Antitumor Effects of PI3Kα Inhibition in PIK3CA- and HRAS-Dysregulated HNSCC via Convergent Inhibition of mTOR Activity
Supplementary figures related to figures 1-5.
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary figures S1-S5 from Tipifarnib Potentiates the Antitumor Effects of PI3Kα Inhibition in PIK3CA- and HRAS-Dysregulated HNSCC via Convergent Inhibition of mTOR Activity
Supplementary figures related to figures 1-5.
- Open Access
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Supplementary figures S1-S5 from Tipifarnib potentiates the antitumor effects of PI3Kα inhibition in PIK3CA- and HRAS-dysregulated HNSCC via convergent inhibition of mTOR activity
Supplementary figures related to figures 1-5.
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary figures S1-S5 from Tipifarnib potentiates the antitumor effects of PI3Kα inhibition in PIK3CA- and HRAS-dysregulated HNSCC via convergent inhibition of mTOR activity
Supplementary figures related to figures 1-5.
- Open Access
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Supplementary figures S1-S5 from Tipifarnib potentiates the antitumor effects of PI3Kα inhibition in PIK3CA- and HRAS-dysregulated HNSCC via convergent inhibition of mTOR activity
Supplementary figures related to figures 1-5.
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary figures S1-S5 from Tipifarnib potentiates the antitumor effects of PI3Kα inhibition in PIK3CA- and HRAS-dysregulated HNSCC via convergent inhibition of mTOR activity
Supplementary figures related to figures 1-5.
- Open Access
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Supplementary figures S1-S5 from Tipifarnib potentiates the antitumor effects of PI3Kα inhibition in PIK3CA- and HRAS-dysregulated HNSCC via convergent inhibition of mTOR activity
Supplementary figures related to figures 1-5.
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary figures S1-S5 from Tipifarnib potentiates the antitumor effects of PI3Kα inhibition in PIK3CA- and HRAS-dysregulated HNSCC via convergent inhibition of mTOR activity
Supplementary figures related to figures 1-5.
- Open Access
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Supplementary figures S1-S5 from Tipifarnib potentiates the antitumor effects of PI3Kα inhibition in PIK3CA- and HRAS-dysregulated HNSCC via convergent inhibition of mTOR activity
Supplementary figures related to figures 1-5.
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary figures S1-S5 from Tipifarnib potentiates the antitumor effects of PI3Kα inhibition in PIK3CA- and HRAS-dysregulated HNSCC via convergent inhibition of mTOR activity
Supplementary figures related to figures 1-5.
- Open Access
- 20 June 2023
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 83 (19) , 3252-3263
Tipifarnib Potentiates the Antitumor Effects of PI3Kα Inhibition in PIK3CA - and HRAS -Dysregulated HNSCC via Convergent Inhibition of mTOR Activity
Outcomes for patients with recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC) are poor, with median overall survival (OS) ranging from 6 to 18 months. For those who progress on standard-of-care (chemo)immunotherapy, treatment options are limited, necessitating the development of rational therapeutic strategies. Toward this end, we targeted the key HNSCC drivers PI3K–mTOR and HRAS via the combination of tipifarnib, a farnesyltransferase (FTase) inhibitor, and alpelisib, a PI3Kα inhibitor, in multiple molecularly defined subsets of HNSCC. Tipifarnib synergized with alpelisib at the level of mTOR in PI3Kα- or HRAS-dependent HNSCCs, leading to marked cytotoxicity in vitro and tumor regression in vivo. On the basis of these findings, the KURRENT-HN trial was launched to evaluate the effectiveness of this combination in PIK3CA-mutant/amplified and/or HRAS-overexpressing R/M HNSCC. Preliminary evidence supports the clinical activity of this molecular biomarker-driven combination therapy. Combined alpelisib and tipifarnib has potential to benefit >45% of patients with R/M HNSCC. By blocking feedback reactivation of mTORC1, tipifarnib may prevent adaptive resistance to additional targeted therapies, enhancing their clinical utility. Significance: The mechanistically designed, biomarker-matched strategy of combining alpelisib and tipifarnib is efficacious in PIK3CA- and HRAS-dysregulated head and neck squamous carcinoma and could improve outcomes for many patients with recurrent, metastatic disease. See related commentary by Lee et al., p. 3162
- 20 June 2023
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 83 (19) , 3252-3263
Open AccessTipifarnib Potentiates the Antitumor Effects of PI3Kα Inhibition in PIK3CA - and HRAS -Dysregulated HNSCC via Convergent Inhibition of mTOR Activity
Outcomes for patients with recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC) are poor, with median overall survival (OS) ranging from 6 to 18 months. For those who progress on standard-of-care (chemo)immunotherapy, treatment options are limited, necessitating the development of rational therapeutic strategies. Toward this end, we targeted the key HNSCC drivers PI3K–mTOR and HRAS via the combination of tipifarnib, a farnesyltransferase (FTase) inhibitor, and alpelisib, a PI3Kα inhibitor, in multiple molecularly defined subsets of HNSCC. Tipifarnib synergized with alpelisib at the level of mTOR in PI3Kα- or HRAS-dependent HNSCCs, leading to marked cytotoxicity in vitro and tumor regression in vivo. On the basis of these findings, the KURRENT-HN trial was launched to evaluate the effectiveness of this combination in PIK3CA-mutant/amplified and/or HRAS-overexpressing R/M HNSCC. Preliminary evidence supports the clinical activity of this molecular biomarker-driven combination therapy. Combined alpelisib and tipifarnib has potential to benefit >45% of patients with R/M HNSCC. By blocking feedback reactivation of mTORC1, tipifarnib may prevent adaptive resistance to additional targeted therapies, enhancing their clinical utility. Significance: The mechanistically designed, biomarker-matched strategy of combining alpelisib and tipifarnib is efficacious in PIK3CA- and HRAS-dysregulated head and neck squamous carcinoma and could improve outcomes for many patients with recurrent, metastatic disease. See related commentary by Lee et al., p. 3162